

## AMENDMENTS TO THE CLAIMS

The listing of claims will replace all prior versions, and listings, of claims in the application.

### Claims:

1. (Currently amended) An oligopeptide having the amino acid sequence:  
Arg-nL-nL-nL-Arg-nL-nL-nL-Gly-Tyr (SEQ ID NO:13).
2. (Currently amended) The oligopeptide according to Claim 21 wherein one or more of the amino acids of said oligopeptide are D isomers.
3. (Currently amended) The oligopeptide according to Claim 32, wherein all the amino acids of said oligopeptide, other than glycine, are D isomers.
4. (Original) The oligopeptide according to any one of Claims 1 to 3, wherein the terminal carboxyl group of said oligopeptide is amidated.
5. (Original) The oligopeptide according to any one of Claims 1 to 4, wherein said oligopeptide is in salt form.
6. (Original) The oligopeptide according to Claim 5, wherein said terminal carboxyl group is the acetate salt of an amide.
7. (Original) An oligopeptide having the structural formula:  
H-(D)Arg-(D)nL-(D)nL-(D)nL-(D)Arg-(D)nL-(D)nL-(D)nL-Gly-(D)Tyr-NH<sub>2</sub> .
8. (Original) A pharmaceutical composition comprising an oligopeptide according to any one of Claims 1 to 7 and a pharmaceutically acceptable medium.

9. (Original) The pharmaceutical composition according to Claim 8, wherein said pharmaceutically acceptable medium comprises an excipient.
10. (Original) The pharmaceutical composition according to Claim 9, wherein said excipient comprises mannitol.